RecruitingEarly Phase 1NCT03746535
Cardiovascular Disease Risk in Women With Endometriosis
Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis
Sponsor
Yale University
Enrollment
40 participants
Start Date
Jul 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria2
- Young women between the ages of 18 and 45 years (Controls);
- Young women between the ages of 18 and 45 years with endometriosis.
Exclusion Criteria4
- Subjects who smoke
- Subjects who have diabetes,
- Subjects with sleep apnea or BP>140/90 will be excluded.
- Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGElagolix
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03746535
Related Trials
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
NCT064395241 location
Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)
NCT0524569510 locations
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
NCT060241092 locations
Imaging of Endometriosis With Total-body PET-CT (PET-Endo)
NCT075239971 location
The Impact of Yoga on Endometriosis-Related Pain
NCT065598521 location